263 related articles for article (PubMed ID: 21725367)
1. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
[TBL] [Abstract][Full Text] [Related]
2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
3. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
[TBL] [Abstract][Full Text] [Related]
4. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
5. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
Adelsman MA; McCarthy JB; Shimizu Y
Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
[TBL] [Abstract][Full Text] [Related]
8. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
9. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.
Roovers K; Wagner S; Storbeck CJ; O'Reilly P; Lo V; Northey JJ; Chmielecki J; Muller WJ; Siegel PM; Sabourin LA
Oncogene; 2009 Aug; 28(31):2839-48. PubMed ID: 19525980
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor.
Hellyer NJ; Kim MS; Koland JG
J Biol Chem; 2001 Nov; 276(45):42153-61. PubMed ID: 11546794
[TBL] [Abstract][Full Text] [Related]
11. ErbB3-dependent motility and intravasation in breast cancer metastasis.
Xue C; Liang F; Mahmood R; Vuolo M; Wyckoff J; Qian H; Tsai KL; Kim M; Locker J; Zhang ZY; Segall JE
Cancer Res; 2006 Feb; 66(3):1418-26. PubMed ID: 16452197
[TBL] [Abstract][Full Text] [Related]
12. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
13. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
14. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells.
Ueno Y; Sakurai H; Tsunoda S; Choo MK; Matsuo M; Koizumi K; Saiki I
Int J Cancer; 2008 Jul; 123(2):340-347. PubMed ID: 18398842
[TBL] [Abstract][Full Text] [Related]
16. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
Vijapurkar U; Cheng K; Koland JG
J Biol Chem; 1998 Aug; 273(33):20996-1002. PubMed ID: 9694850
[TBL] [Abstract][Full Text] [Related]
17. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
18. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.
Knowlden JM; Gee JM; Barrow D; Robertson JF; Ellis IO; Nicholson RI; Hutcheson IR
Breast Cancer Res; 2011 Sep; 13(5):R93. PubMed ID: 21939528
[TBL] [Abstract][Full Text] [Related]
19. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
